نتایج جستجو برای: alisertib
تعداد نتایج: 124 فیلتر نتایج به سال:
PURPOSE Aurora A kinase (AAK) is a key regulator of mitosis and a target for anticancer drug development. This phase I study investigated the safety, pharmacokinetics, and pharmacodynamics of MLN8237 (alisertib), an investigational, oral, selective AAK inhibitor, in 59 adults with advanced solid tumors. EXPERIMENTAL DESIGN Patients received MLN8237 once daily or twice daily for 7, 14, or 21 c...
Acute lymphoblastic leukemia (ALL) with translocation t(17;19)(q21-q22;p13) TCF3::HLF (E2A::HLF) accounts for less than 1% of childhood B-lineage ALL. Since the first description, patients this type ALL are stratified into high-risk group. The disease often has a unique clinical presentation disseminated intravascular coagulation and hypercalcemia, that uncommon in other types This is character...
Background: Copanlisib, a pan-PI3K inhibitor with stronger activity against the alpha and delta isoforms, is Food Drug Administration (FDA) approved for treatment of patients relapsed or refractory follicular lymphoma, it has shown clinical in other indolent lymphomas including marginal zone lymphoma (MZL). Preclinical studies have demonstrated strong synergism copanlisib BCL2 venetoclax differ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید